Innate Pharma

Innate Pharma announces its financial calendar for 2017

January 4, 2017

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2017, which is set as follows: March 7, 2017 : Publication of 2016 financial statements...

Number of shares and voting rights of Innate Pharma as of July 3, 2025

July 4, 2025

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...

Innate Pharma announces its participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

June 17, 2025

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team will participate in the upcoming investor conferences, detailed...

Innate Pharma highlights preclinical antitumor activity of IPH6501 in diffuse large B-cell lymphoma and follicular lymphoma at the 2025 European Hematology Association (EHA) congress

June 13, 2025

Preclinical data from IPH6501, Innate’s proprietary ANKET ® targeting CD20, demonstrating potent antitumor activity in vitro on patient-derived samples from Diffuse Large B-Cell Lymphoma (DLBCL) and...

Tina Cascone et al, 2025. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial Nature Medicine

Jonathan Dickinson, Chief Executive Officer of Innate Pharma

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

May 27, 2025

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its executive team will present and host 1x1 meetings at the upcoming investor...

Outcome of Innate Pharma’s 2025 Annual General Meeting

May 23, 2025

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 22...

Christian ITIN

CEO of Autolus

Innate Pharma highlights durable responses to lacutamab in Sezary syndrome and mycosis fungoides

May 23, 2025

Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented at the ASCO Annual Meeting 2025. Long-term follow-up data from TELLOMAK...